Nexgel Inc

Nexgel Inc(NXGL)の株式分析

$3.720

-0.359 (-9.65%)終値時点

Loading chart…
高値
3.800
始値
3.800
出来高加重平均価格
3.71
出来高
13.83K
時価総額
13.55M
安値
3.600
売買代金
51.27K
EV/EBITDA(TTM)
-0.61

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

nexgel.com

AI分析 of Nexgel Inc (NXGL)

売り

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

バリュエーション指標

Nexgel Inc(NXGL)の現在の予想PERは1.38で、5年平均は-12.03です。

予想PER

適正
5年平均 P/E
-12.03
現在のP/E
1.38
割高
8.24
割安
-32.31

予想EV/EBITDA

適正
5年平均 EV/EBITDA
20.87
現在のEV/EBITDA
-0.61
割高
104.38
割安
-62.63

予想PSR

割安
5年平均 P/S
2.06
現在のP/S
0.08
割高
3.55
割安
0.56

Alphio AI による NXGL の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%NXGL

$6.00

シナリオ価格

基

基本

基本 · 50%NXGL

$5.53

シナリオ価格

弱

弱気

弱気 · 25%NXGL

$5.37

シナリオ価格

イベントタイムライン

2026-10-09 (ET)

20:00:00

Nexgel Inc Trading Halted, News Pending

2026-08-20 (ET)

16:30:00

NexGel Appoints Brian Kieser as Interim CEO

16:30:00

Company Establishes Special Committee for Strategic Review

13:00:00

Selling Stockholders Plan to Sell 15.25M Shares of Common Stock

2026-05-19 (ET)

09:20:00

NexGel Reports Clinical Study Data Showing 37.2% Reduction in Hair Density

ニュース

NXGL のよくある質問 — Alphio AI が回答

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める